Kolexia
Genet Dominique Oncologie médicale
Genet Dominique
Oncologie médicale
Centre Hospitalier d'Ussel
Ussel, France
66 Activités
54 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du sein Tumeurs du côlon Métastase tumorale Tumeurs du rectum Tumeurs du foie Thrombose veineuse Carcinome pulmonaire non à petites cellules Thrombose

Collaborateurs

Voir plus
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Francois Eric
Francois Eric
Centre Antoine Lacassagne, Nice, France
Aparicio Thomas
Aparicio Thomas
Hôpital Avicenne, Bobigny, France
Faroux Roger
Faroux Roger
Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France

Industries

Voir plus
Novartis
10 collaboration(s)
Dernière en 2023
AstraZeneca
7 collaboration(s)
Dernière en 2023
Pfizer
3 collaboration(s)
Dernière en 2022
MSD
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA network open   05 septembre 2023
VIDÉO. "ce sont comme des brûlures" : cancer du sein, ces douleurs qu ...
France 2 Régions   25 juillet 2023
VIDÉO. À Limoges, on traite la douleur après un cancer du sein
France 2 Régions   22 mai 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
Therapeutic advances in medical oncology   26 décembre 2022
387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
2022 ASCO Annual Meeting I   02 juin 2022
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Abstract Book of ESMO Breast Cancer 2022, Berlin, Germany, 03-05 May 2022   01 mai 2022
TIME: Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Essai Clinique (Unicancer)   23 mars 2022
Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
British journal of cancer   29 septembre 2021